Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors

  • Neeb, Antje
  • Herranz Martín, Nicolás
  • Arce-Gallego, Sara
  • Buroni, Lorenzo
  • Athie Cuervo, Alejandro
  • Casanova Salas, Irene
  • González Rodríguez, Macarena
  • Morales Barrera, Rafael
  • Suárez Rodríguez, Cristina
  • Carles Galceran, Joan
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Miranda, Susana
  • Cordoba, Sarai
  • Castro, Natalia
  • Yuan, Wei
  • Casals, Teresa
Inhibició de l’ATR; Resposta de danys a l’ADN; Càncer de pròstata, Inhibición de ATR; Respuesta al daño del ADN; Cancer de prostata, ATR inhibition; DNA damage response; Prostate cancer, Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. Objective To characterise ATM-deficient lethal PC and to study synthetic lethal therapeutic strategies for this subset. Design, setting, and participants We studied advanced PC biopsies using validated immunohistochemical (IHC) and next-generation sequencing (NGS) assays. In vitro cell line models modified using CRISPR-Cas9 to impair ATM function were generated and used in drug-sensitivity and functional assays, with validation in a patient-derived model. Outcome measurements and statistical analysis ATM expression by IHC was correlated with clinical outcome using Kaplan-Meier curves and log-rank test; sensitivity to different drug combinations was assessed in the preclinical models. Results and limitations Overall, we detected ATM IHC loss in 68/631 (11%) PC patients in at least one biopsy, with synchronous and metachronous intrapatient heterogeneity; 46/71 (65%) biopsies with ATM loss had ATM mutations or deletions by NGS. ATM IHC loss was not associated with worse outcome from advanced disease, but ATM loss was associated with increased genomic instability (NtAI:number of subchromosomal regions with allelic imbalance extending to the telomere, p = 0.005; large-scale transitions, p = 0.05). In vitro, ATM loss PC models were sensitive to ATR inhibition, but had variable sensitivity to PARP inhibition; superior antitumour activity was seen with combined PARP and ATR inhibition in these models. Conclusions ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition., We gratefully acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence ( CEO13_2-002 ), the Prostate Cancer Foundation (including Young Investigator Awards to Joaquin Mateo, Pasquale Rescigno, and Adam Sharp), Stand Up To Cancer, and the UK Department of Health through an Experimental Cancer Medicine Centre grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Part of this work was also funded by a Deparment of Defense CDMRP Impact Award (W81XWH-18-1-0756) to Joaquin Mateo and by Instituto de Salud Carlos III through Grant FI19/00280 to Sara Arce-Gallego, Grant CP19/00170 to Nicolás Herranz, and Grant PI18/01384 to Joaquin Mateo. The authors affiliated to VHIO acknowledge the “la Caixa” Foundation ( ID 100010434 ) for funding under agreement LCF/PR/PR17/51120011 and funding from Fundacion FERO and Moventia . This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 837900 . The funding organisations had no role in the design, conduction or data analysis of this project, neither in the manuscript preparation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence

  • Arce Gallego, Sara
  • Romero-Lozano, Paula
  • Mir Arnau, Gisela
  • Aguilar, Daniel
  • Mast, Richard
  • Cresta Morgado, Pablo
  • Delgado-Serrano, Luisa
  • Simonetti, Sara
  • Macarena, Gonzalez
  • Marmolejo Castañeda, David Humberto
  • Morales-Barrera, Rafael
  • Semidey Raven, Maria Eugenia
  • Cordoba, Sarai
  • de Albert de Delás-Vigo, Matias
  • Planas, Jacques
  • Cuadras Solé, Mercè
  • Maldonado, Xavier
  • Casanova-Salas, Irene
  • Mas Malavila, Alba
  • Nonell, Lara
  • Dienstmann, Rodrigo
  • Nuciforo, Paolo
  • Vivancos, Ana
  • Llop-Guevara, Alba
  • Mateo, Joaquin
  • Carles, Joan
  • Suárez, Cristina
  • Serra, Violeta
Genomics; Immunofluorescence; Prostate cancer, Genòmica; Immunofluorescència; Càncer de pròstata, Genómica; Inmunofluorescencia; Cáncer de próstata, Metastatic prostate cancer (mPC) is enriched for homologous recombination repair (HRR) gene alterations, which have prognostic and predictive value. Routine clinical implementation of next-generation sequencing (NGS) is still limited. We investigated the association between genomic and functional loss of HRR, using NGS and RAD51 immunofluorescence (RAD51-IF) in 219 primary or metastatic biopsies from 187 patients with stage IV prostate cancer. NGS showed frequent genomic alterations in TP53 (40%), AR (15%), PTEN (14%), FOXA1 (12%), MYC (10%), BRCA2 (9%), ATM (8%), and BRCA1 (2%). We pursued RAD51-IF in 206 samples; of those, 139/206 (67%) were evaluable. 21% of samples had RAD51-low score compatible with HRR deficiency (HRD). RAD51-IF showed high sensitivity (71%) and specificity (86%) for BRCA1/2 alterations. Patients with RAD51-low scores experienced longer progression-free survival (PFS) on poly(ADP-ribose) polymerase inhibitors (PARPi) or platinum chemotherapy. RAD51-IF is feasible in routine clinical samples from patients with mPC and is associated with clinically relevant HRR gene alterations., This work was funded by an Impact Award from the Department of Defense CDMRP (PC170510P1) and a grant from AstraZeneca (ESR-21-21360). The funders had no role in the design or conduction of the study and were not involved in the analysis or interpretation of results. CRIS Cancer Foundation (grant TCL_2020-10) and Fundación AECC (LABAE20019MATE) and a Department of Defense Physician Science Award to J.M. (PC220307). S.A.-G. was supported by Instituto de Salud Carlos III (FI19/00280). P.C.M. was supported by an ESMO Translational Research Fellowship, funded by BMS (any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO or BMS). I.C.-S. was supported by a Prostate Cancer Foundation YIA (24YOU12). A.L.-G. was supported by an AECC grant (INVES20095LLOP), and V.S. received funding from an ERA PerMed grant (ERAPERMED2019-215). The VHIO authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for its financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the CERCA Program from the Generalitat de Catalunya for their support of this research.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer

  • Arce Gallego, Sara
  • Esquefa, Victor
  • Domènech Garcia, Heura
  • Aguilar Villalba, Daniel
  • Casals, Teresa
  • Oliveira Tercero, Anna
  • de Llobet Cucalón, Lara
  • Anselmino, Nicolás
  • Herranz, Nicolas
  • Salca, Andrei
  • Mir Arnau, Gisela
  • Simonetti, Sara
  • Brandariz, Julian
  • Casanova-Salas, Irene
  • Mateo, Joaquin
  • Serra, Violeta
Combination therapy; PARPi inhibitors; Prostate cancer, Teràpia combinada; Inhibidors de PARPi; Càncer de pròstata, Terapia combinada; inhibidores de PARPi; Cáncer de próstata, PARP inhibitors (PARPi) are approved treatments for patients with metastatic prostate cancer (mPC); tumors with homologous recombination repair (HRR) defects are particularly sensitive to this drug class. While previous work has associated ATM defects with response to PARPi, its predictive value remains controversial and the mechanisms underlying sensitivity and eventual acquired drug resistance in this setting remain unclear. To address this, we generated in vitro prostate cancer models of acquired PARPi resistance to olaparib and saruparib, a novel selective PARP1 inhibitor and pursued functional characterization and drug sensitivity studies. We found that resistant models bypass the G2/M arrest induced by PARPi in sensitive models; and display a greater reliance on the ATR-dependent response to DNA damage and replication stress, mainly through the ATR-CHK1 axis. Consistently, we demonstrate in vivo that the combination of PARPi-ATRi in resistant models restores treatment sensitivity through enhancing replication stress. Collectively, these findings highlight an interplay between ATM-ATR signaling as a key mediator of PARPi sensitivity in ATM-deficient mPC and identify a promising therapeutic combination to prolong treatment response and potentially improve patients’ outcomes., This work was supported by funding from the CRIS Cancer Foundation (grant TCL_2020-10 to J. Mateo) and Fundación AECC (LABAE20019MATE), as well as a grant from the AstraZeneca Partners of Choice program (POC5270-10045025). Sara Arce-Gallego was supported by Instituto de Salud Carlos III (FI19/00280); Irene Casanova-Salas was supported by a Prostate Cancer Foundation YIA (24YOU12); Violeta Serra received funding from an ERA PerMed grant (ERAPERMED2019-215). We also acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for the financial support to VHIO as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Program from the Generalitat de Catalunya for their support on this research. We also would like to acknowledge Dr Lara Nonell and the Bioinformatics Unit at VHIO for their support in NGS analysis and Dr Tian Tian at VHIO for providing the SceI-BFP conjugated enzyme.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

  • Carreira, Suzanne
  • Porta, Nuria
  • Arce-Gallego, Sara
  • Llop Guevara, Alba
  • Bianchini, Diletta
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Seed, George
Pròstata; PARP; Biomarcadors, Próstata; PARP; Biomarcadores, Prostate; PARP; biomarkers, PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B Phase II clinical trial samples, evaluating whole exome and low-pass whole genome sequencing and immunohistochemical assays evaluating ATM and RAD51 foci (testing homologous recombination repair function). BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion. Biallelic, but not mono-allelic, PALB2 deleterious alterations were associated with clinical benefit. In the ATM cohort, loss of ATM protein by immunohistochemistry associated with better outcome. RAD51 foci loss identified tumors with biallelic BRCA and PALB2 alteration while most ATM- and CDK12-altered APCs had higher RAD51 foci levels. Overall, APCs with homozygous BRCA2 deletion are exceptional responders; PALB2 biallelic loss and loss of ATM immunohistochemical expression associated with clinical benefit., TOPARP is an investigator-initiated trial; we are grateful for the support and funding from AstraZeneca, and for the study grants from Cancer Research UK (CRUK/11/029; C12540/A12829; C12540/A13230; C12540/A20447). ICR-CTSU also receives program grant funding from Cancer Research UK (Grant number: C1491/A15955, C1491/A25351). We acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002), the Prostate Cancer Foundation, and the UK Department of Health through an Experimental Cancer Medicine Centre (ECMC) grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Pasquale Rescigno was supported by a PCF Young Investigator Award 19YOUN19. The authors affiliated to VHIO acknowledge funding from “La Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 (LCF/TR/CC19/52470003), Fundacion FERO and Fundacion Cellex. J. Mateo, A. Llop-Guevara and V. Serra received grants from Fundacion Cientifica AECC (LABAE16020PORTT) and an ERAPERMED2019-215. J. Mateo gratefully acknowledges funding from the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant 837900), Instituto de Salud Carlos III (Grant PI18/01384), Fundación AECC, CRIS Cancer Foundation and the US Department of Defense CDMRP (Impact Award PC170510P1). S. Arce-Gallego Research. Downloaded from cancerdiscovery.aacrjournals.org on July 1, 2021. © 2021 American Association for Cancer Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 27, 2021; DOI: 10.1158/2159-8290.CD-21-0007 3 and V. Serra were supported by Instituto de Salud Carlos III (FI19/00280, CPII19/00033).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer

  • Arce Gallego, Sara
  • Esquefa, Victor
  • Domènech Garcia, Heura
  • Aguilar Villalba, Daniel
  • Casals, Teresa
  • Oliveira Tercero, Anna
  • de Llobet Cucalón, Lara
  • Anselmino, Nicolás
  • Herranz, Nicolas
  • Salca, Andrei
  • Mir Arnau, Gisela
  • Simonetti, Sara
  • Brandariz, Julian
  • Casanova-Salas, Irene
  • Mateo, Joaquin
  • Serra, Violeta
Combination therapy; PARPi inhibitors; Prostate cancer, Teràpia combinada; Inhibidors de PARPi; Càncer de pròstata, Terapia combinada; inhibidores de PARPi; Cáncer de próstata, PARP inhibitors (PARPi) are approved treatments for patients with metastatic prostate cancer (mPC); tumors with homologous recombination repair (HRR) defects are particularly sensitive to this drug class. While previous work has associated ATM defects with response to PARPi, its predictive value remains controversial and the mechanisms underlying sensitivity and eventual acquired drug resistance in this setting remain unclear. To address this, we generated in vitro prostate cancer models of acquired PARPi resistance to olaparib and saruparib, a novel selective PARP1 inhibitor and pursued functional characterization and drug sensitivity studies. We found that resistant models bypass the G2/M arrest induced by PARPi in sensitive models; and display a greater reliance on the ATR-dependent response to DNA damage and replication stress, mainly through the ATR-CHK1 axis. Consistently, we demonstrate in vivo that the combination of PARPi-ATRi in resistant models restores treatment sensitivity through enhancing replication stress. Collectively, these findings highlight an interplay between ATM-ATR signaling as a key mediator of PARPi sensitivity in ATM-deficient mPC and identify a promising therapeutic combination to prolong treatment response and potentially improve patients’ outcomes., This work was supported by funding from the CRIS Cancer Foundation (grant TCL_2020-10 to J. Mateo) and Fundación AECC (LABAE20019MATE), as well as a grant from the AstraZeneca Partners of Choice program (POC5270-10045025). Sara Arce-Gallego was supported by Instituto de Salud Carlos III (FI19/00280); Irene Casanova-Salas was supported by a Prostate Cancer Foundation YIA (24YOU12); Violeta Serra received funding from an ERA PerMed grant (ERAPERMED2019-215). We also acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for the financial support to VHIO as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Program from the Generalitat de Catalunya for their support on this research. We also would like to acknowledge Dr Lara Nonell and the Bioinformatics Unit at VHIO for their support in NGS analysis and Dr Tian Tian at VHIO for providing the SceI-BFP conjugated enzyme.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors

  • Neeb, Antje
  • Herranz Martín, Nicolás
  • Arce Gallego, Sara
  • Buroni, Lorenzo
  • Athie Cuervo, Alejandro
  • Casanova Salas, Irene
  • González Rodríguez, Macarena
  • Morales Barrera, Rafael
  • Suárez Rodríguez, Cristina
  • Carles Galceran, Joan
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Miranda, Susana
  • Cordoba, Sarai
  • Castro, Natalia
  • Yuan, Wei
  • Casals, Teresa
Inhibició de l’ATR; Resposta de danys a l’ADN; Càncer de pròstata, Inhibición de ATR; Respuesta al daño del ADN; Cancer de prostata, ATR inhibition; DNA damage response; Prostate cancer, Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. Objective To characterise ATM-deficient lethal PC and to study synthetic lethal therapeutic strategies for this subset. Design, setting, and participants We studied advanced PC biopsies using validated immunohistochemical (IHC) and next-generation sequencing (NGS) assays. In vitro cell line models modified using CRISPR-Cas9 to impair ATM function were generated and used in drug-sensitivity and functional assays, with validation in a patient-derived model. Outcome measurements and statistical analysis ATM expression by IHC was correlated with clinical outcome using Kaplan-Meier curves and log-rank test; sensitivity to different drug combinations was assessed in the preclinical models. Results and limitations Overall, we detected ATM IHC loss in 68/631 (11%) PC patients in at least one biopsy, with synchronous and metachronous intrapatient heterogeneity; 46/71 (65%) biopsies with ATM loss had ATM mutations or deletions by NGS. ATM IHC loss was not associated with worse outcome from advanced disease, but ATM loss was associated with increased genomic instability (NtAI:number of subchromosomal regions with allelic imbalance extending to the telomere, p = 0.005; large-scale transitions, p = 0.05). In vitro, ATM loss PC models were sensitive to ATR inhibition, but had variable sensitivity to PARP inhibition; superior antitumour activity was seen with combined PARP and ATR inhibition in these models. Conclusions ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition., We gratefully acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence ( CEO13_2-002 ), the Prostate Cancer Foundation (including Young Investigator Awards to Joaquin Mateo, Pasquale Rescigno, and Adam Sharp), Stand Up To Cancer, and the UK Department of Health through an Experimental Cancer Medicine Centre grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Part of this work was also funded by a Deparment of Defense CDMRP Impact Award (W81XWH-18-1-0756) to Joaquin Mateo and by Instituto de Salud Carlos III through Grant FI19/00280 to Sara Arce-Gallego, Grant CP19/00170 to Nicolás Herranz, and Grant PI18/01384 to Joaquin Mateo. The authors affiliated to VHIO acknowledge the “la Caixa” Foundation ( ID 100010434 ) for funding under agreement LCF/PR/PR17/51120011 and funding from Fundacion FERO and Moventia . This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 837900 . The funding organisations had no role in the design, conduction or data analysis of this project, neither in the manuscript preparation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

  • Carreira, Suzanne
  • Porta, Nuria
  • Arce Gallego, Sara
  • Llop Guevara, Alba
  • Bianchini, Diletta
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Seed, George
Pròstata; PARP; Biomarcadors, Próstata; PARP; Biomarcadores, Prostate; PARP; biomarkers, PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B Phase II clinical trial samples, evaluating whole exome and low-pass whole genome sequencing and immunohistochemical assays evaluating ATM and RAD51 foci (testing homologous recombination repair function). BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion. Biallelic, but not mono-allelic, PALB2 deleterious alterations were associated with clinical benefit. In the ATM cohort, loss of ATM protein by immunohistochemistry associated with better outcome. RAD51 foci loss identified tumors with biallelic BRCA and PALB2 alteration while most ATM- and CDK12-altered APCs had higher RAD51 foci levels. Overall, APCs with homozygous BRCA2 deletion are exceptional responders; PALB2 biallelic loss and loss of ATM immunohistochemical expression associated with clinical benefit., TOPARP is an investigator-initiated trial; we are grateful for the support and funding from AstraZeneca, and for the study grants from Cancer Research UK (CRUK/11/029; C12540/A12829; C12540/A13230; C12540/A20447). ICR-CTSU also receives program grant funding from Cancer Research UK (Grant number: C1491/A15955, C1491/A25351). We acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002), the Prostate Cancer Foundation, and the UK Department of Health through an Experimental Cancer Medicine Centre (ECMC) grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Pasquale Rescigno was supported by a PCF Young Investigator Award 19YOUN19. The authors affiliated to VHIO acknowledge funding from “La Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 (LCF/TR/CC19/52470003), Fundacion FERO and Fundacion Cellex. J. Mateo, A. Llop-Guevara and V. Serra received grants from Fundacion Cientifica AECC (LABAE16020PORTT) and an ERAPERMED2019-215. J. Mateo gratefully acknowledges funding from the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant 837900), Instituto de Salud Carlos III (Grant PI18/01384), Fundación AECC, CRIS Cancer Foundation and the US Department of Defense CDMRP (Impact Award PC170510P1). S. Arce-Gallego Research. Downloaded from cancerdiscovery.aacrjournals.org on July 1, 2021. © 2021 American Association for Cancer Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 27, 2021; DOI: 10.1158/2159-8290.CD-21-0007 3 and V. Serra were supported by Instituto de Salud Carlos III (FI19/00280, CPII19/00033).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence

  • Arce Gallego, Sara
  • Romero-Lozano, Paula
  • Mir Arnau, Gisela
  • Aguilar, Daniel
  • Mast, Richard
  • Cresta Morgado, Pablo
  • Delgado-Serrano, Luisa
  • Simonetti, Sara
  • Macarena, Gonzalez
  • Marmolejo Castañeda, David Humberto
  • Morales-Barrera, Rafael
  • Semidey Raven, Maria Eugenia
  • Cordoba, Sarai
  • de Albert de Delás-Vigo, Matias
  • Planas, Jacques
  • Cuadras Solé, Mercè
  • Maldonado, Xavier
  • Casanova-Salas, Irene
  • Mas Malavila, Alba
  • Nonell, Lara
  • Dienstmann, Rodrigo
  • Nuciforo, Paolo
  • Vivancos, Ana
  • Llop-Guevara, Alba
  • Mateo, Joaquin
  • Carles, Joan
  • Suárez, Cristina
  • Serra, Violeta
Genomics; Immunofluorescence; Prostate cancer, Genòmica; Immunofluorescència; Càncer de pròstata, Genómica; Inmunofluorescencia; Cáncer de próstata, Metastatic prostate cancer (mPC) is enriched for homologous recombination repair (HRR) gene alterations, which have prognostic and predictive value. Routine clinical implementation of next-generation sequencing (NGS) is still limited. We investigated the association between genomic and functional loss of HRR, using NGS and RAD51 immunofluorescence (RAD51-IF) in 219 primary or metastatic biopsies from 187 patients with stage IV prostate cancer. NGS showed frequent genomic alterations in TP53 (40%), AR (15%), PTEN (14%), FOXA1 (12%), MYC (10%), BRCA2 (9%), ATM (8%), and BRCA1 (2%). We pursued RAD51-IF in 206 samples; of those, 139/206 (67%) were evaluable. 21% of samples had RAD51-low score compatible with HRR deficiency (HRD). RAD51-IF showed high sensitivity (71%) and specificity (86%) for BRCA1/2 alterations. Patients with RAD51-low scores experienced longer progression-free survival (PFS) on poly(ADP-ribose) polymerase inhibitors (PARPi) or platinum chemotherapy. RAD51-IF is feasible in routine clinical samples from patients with mPC and is associated with clinically relevant HRR gene alterations., This work was funded by an Impact Award from the Department of Defense CDMRP (PC170510P1) and a grant from AstraZeneca (ESR-21-21360). The funders had no role in the design or conduction of the study and were not involved in the analysis or interpretation of results. CRIS Cancer Foundation (grant TCL_2020-10) and Fundación AECC (LABAE20019MATE) and a Department of Defense Physician Science Award to J.M. (PC220307). S.A.-G. was supported by Instituto de Salud Carlos III (FI19/00280). P.C.M. was supported by an ESMO Translational Research Fellowship, funded by BMS (any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO or BMS). I.C.-S. was supported by a Prostate Cancer Foundation YIA (24YOU12). A.L.-G. was supported by an AECC grant (INVES20095LLOP), and V.S. received funding from an ERA PerMed grant (ERAPERMED2019-215). The VHIO authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for its financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the CERCA Program from the Generalitat de Catalunya for their support of this research.